10-Q: DURECT Q2: Bausch Health Acquisition Pending

DURECT Corporation reported reduced losses in Q2 2025, with a pending acquisition by Bausch Health offering $1.75 per share plus contingent value rights.

Summary

• DURECT Corporation reported a net loss of $2.3 million for the three months ended June 30, 2025, an improvement from a $3.7 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $6.5 million, significantly lower than the $11.3 million loss for the corresponding period in 2024.
• Total revenues decreased to $447,000 for Q2 2025 and $768,000 for the six months ended June 30, 2025, down from $646,000 and $1.142 million respectively in 2024, primarily due to lower earn-out revenue from Indivior.
• Research and development expenses decreased to $1.2 million for Q2 2025 and $3.1 million for the six months ended June 30, 2025, compared to $2.2 million and $6.4 million in the prior year, mainly due to lower larsucosterol-related costs.
• Selling, general and administrative expenses also decreased to $2.1 million for Q2 2025 and $4.6 million for the six months, down from $2.6 million and $5.2 million in 2024, due to lower employee costs.
• Cash, cash equivalents, and investments totaled $6.7 million as of June 30, 2025, a decrease from $12.0 million at December 31, 2024.
• The company used $5.3 million in cash from operating activities for the six months ended June 30, 2025, an improvement from $10.4 million used in the prior year period.
• A definitive agreement was announced on July 29, 2025, for Bausch Health Americas, Inc. to acquire DURECT for $1.75 per share in cash upfront, plus two potential net sales milestone payments totaling up to $350 million in aggregate via non-tradeable contingent value rights (CVRs) related to larsucosterol.
• The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions including a majority of outstanding shares being tendered.
• Larsucosterol, the lead candidate in DURECT's Epigenetic Regulator Program for alcohol-associated hepatitis (AH), received Breakthrough Therapy Designation (BTD) from the FDA in May 2024.
• Phase 2b AHFIRM trial showed clinically meaningful trends in 90-day mortality reduction for larsucosterol (41% for 30mg, 35% for 90mg vs. placebo), with more pronounced reductions in U.S. patients (57% for 30mg, 58% for 90mg).
• The company regained compliance with Nasdaq's Minimum Bid Price Requirement on August 12, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the pending acquisition by Bausch Health, which offers a significant upfront cash payment and potential future upside through CVRs, effectively resolving the company's long-standing going concern issues and providing a clear exit for shareholders. The Breakthrough Therapy Designation for larsucosterol further enhances its value. While current revenues are down and losses persist, the acquisition fundamentally changes the company's financial trajectory and risk profile.

Positives

• Net loss significantly decreased to $2.3 million in Q2 2025 from $3.7 million in Q2 2024, and to $6.5 million for the six months ended June 30, 2025, from $11.3 million in the prior year period.
• Cash used in operating activities improved to $5.3 million for the six months ended June 30, 2025, compared to $10.4 million in the same period of 2024.
• Larsucosterol received Breakthrough Therapy Designation (BTD) from the FDA for alcohol-associated hepatitis (AH), which can expedite development and review.
• The Phase 2b AHFIRM trial for larsucosterol showed clinically meaningful trends in reducing 90-day mortality, particularly in U.S. patients (57-58% reduction), and was safe and well tolerated.
• The pending acquisition by Bausch Health provides a clear path for DURECT shareholders to receive cash and potential future upside through CVRs, addressing the company's going concern issues.
• DURECT regained compliance with the Nasdaq Minimum Bid Price Requirement on August 12, 2025, resolving a potential delisting issue.

Negatives

• Total revenues declined to $447,000 in Q2 2025 from $646,000 in Q2 2024, and to $768,000 for the six months ended June 30, 2025, from $1.142 million in the prior year period.
• The company continues to incur significant operating losses, with an accumulated deficit of $603.8 million as of June 30, 2025.
• Cash, cash equivalents, and investments decreased to $6.7 million at June 30, 2025, from $12.0 million at December 31, 2024, indicating continued cash burn.
• Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements, and auditors issued a going concern opinion for FY2024.
• The primary endpoint of mortality or liver transplant at 90 days in the AHFIRM trial did not achieve statistical significance for either dose of larsucosterol.
• Innocoll terminated the license agreement for POSIMIR, requiring DURECT to seek a new partner for commercialization.
• Indivior discontinued sales and marketing for PERSERIS, eliminating a source of earn-out revenue.

Risks

• The consummation of the merger with Bausch Health is subject to numerous conditions, many outside of the company's control, and may not be completed within the expected timeframe or at all.
• Failure to complete the merger could adversely affect the stock price, business, and financial results, and may require DURECT to pay a $3.5 million termination fee.
• During the merger's pendency, DURECT is subject to business uncertainties and contractual restrictions, potentially affecting relationships with customers, vendors, and employees, and limiting strategic actions.
• Shareholders may not receive any payment on the contingent value rights (CVRs) if the larsucosterol net sales milestones ($500 million and $1 billion worldwide annual sales) are not achieved by December 31, 2045, or within 10 years of first commercial sale in the U.S.
• Potential litigation challenging the merger could delay or prevent its completion and incur significant costs.
• Disruptions at the FDA due to funding shortages, personnel changes, or policy shifts (e.g., under a new administration) could hinder timely reviews and approvals of product candidates, including larsucosterol.
• The company's ability to continue as a going concern is dependent on securing additional funding through collaborations, equity, or debt financing, which is not assured.

Future Outlook

The company anticipates continued losses and negative cash flows from operations for the foreseeable future, although cash used in core operating activities is expected to decrease in the near term. The primary future outlook is dominated by the pending acquisition by Bausch Health, expected to close in Q3 2025, which would transform the company into a wholly-owned subsidiary. If the merger is not completed, the company will require substantial additional funding through various financing activities to continue research and development, including a planned Phase 3 clinical trial for larsucosterol in AH, and to meet operating cash flow requirements.

Management Comments

• The Board of Directors unanimously determined that entering into the Merger Agreement and consummating the transactions are in the best interests of the company and its stockholders, and resolved to recommend that stockholders accept the tender offer.
• Management plans to meet operating cash flow requirements by seeking additional collaborative agreements and financing activities such as public/private offerings of common stock, preferred stock, or debt instruments, if the merger does not close.

Industry Context

The biopharmaceutical industry, particularly in the acute organ injury and chronic liver disease space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. DURECT's focus on epigenetic therapies, specifically larsucosterol for alcohol-associated hepatitis (AH) and metabolic dysfunction-associated steatohepatitis (MASH), positions it in a high-need area with limited approved therapeutics. The acquisition by Bausch Health reflects a trend of larger pharmaceutical companies acquiring smaller biotech firms with promising late-stage assets, providing a strategic exit for DURECT and potentially accelerating larsucosterol's path to market with greater resources. The competitive landscape for AH and MASH treatments is evolving, with larsucosterol's Breakthrough Therapy Designation offering a competitive advantage.

Comparison to Industry Standards

• The filing does not contain specific comparable company, project, or results data to assess DURECT's performance against global benchmarks.

Legal Proceedings

• The company is not a party to any material legal proceedings.

Stakeholder Impact

• Shareholders: Will receive $1.75 per share in cash and one non-tradeable CVR per share upon merger completion, offering a defined return and potential future upside.
• Employees: The pendency of the merger may create uncertainty and impact the company's ability to retain and incentivize key personnel.
• Customers and Suppliers: Existing or prospective relationships may be adversely affected by the merger announcement, potentially delaying decisions or changing business terms.
• Creditors: The payoff of the term loan with Oxford Finance LLC in November 2024 has resolved prior debt obligations.

Next Steps

• Consummation of the tender offer and merger with Bausch Health, expected in the third quarter of 2025.
• If the merger is not completed, the company will evaluate next steps for commercializing POSIMIR after Innocoll's termination of the license agreement.
• If the merger is not completed, the company plans to initiate a Phase 3 clinical trial for larsucosterol in AH and present topline results within two years of initiation, contingent on obtaining sufficient capital resources.
• The company intends to seek and enter into strategic alliances and collaborations.

Key Dates

Recommendation

For a seasoned investor, the recommendation is 'hold' because the company is subject to a definitive merger agreement. While the upfront cash consideration of $1.75 per share provides a floor, the non-tradeable contingent value rights (CVRs) offer potential additional value up to $350 million based on future larsucosterol sales milestones. Holding allows participation in this potential upside, although the CVRs are non-tradeable and their value is contingent and uncertain. A 'sell' recommendation would be appropriate for investors seeking to immediately realize the cash value and avoid the CVR's speculative nature and illiquidity, but holding offers the chance for a higher total return if larsucosterol succeeds commercially under Bausch Health.

Keywords

Biopharmaceutical, Alcohol-associated Hepatitis, Larsucosterol, Merger, Acquisition, Bausch Health, Clinical Trials, Drug Development, SEC Filing, 10-Q, Liver Disease, Epigenetic Therapy, Breakthrough Therapy Designation, Contingent Value Rights